Sopharma Group has acquired two pharmaceutical products in Poland
November 2023 — Sopharma Group has acquired Coffepirine and Kopiryna, two highly recognized medicines to treat headache. The acquisition will further expand the market presence of Sopharma Group in the Polish market and support the promising potential of the two pharmaceutical drugs.
Sopharma Group is a leading producer and distributor of healthcare products in the CEE, with a vertically integrated business model running through the whole value chain, with its own R&D, manufacturing and wholesale and retail distribution. The company is present in 33 countries and has a portfolio consisting of more than 200 products.
Coffepirine and Kopiryna are OTC analgesics with APIs based on a combination of acetylsalicylic acid and caffeine, which have helped the Polish public to treat headaches for decades. The drugs are developed and manufactured by Medicofarma, a well-known Polish pharmaceuticals company.
Medicofarma is a pharmaceutical manufacturing company focusing on contract manufacturing of pharmaceuticals, medicinal products and dietary supplements. The company has a modern factory equipped with state-of-the-art technology and meets all GMP requirements.
Our role in the transaction
Oaklins’ team in Bulgaria acted as buy-side advisor to Sopharma Group, leading the transaction process, deal structuring and negotiations, and assisting throughout the acquisition process.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn more